Tirzepatide vs Retatrutide
Tirzepatide is a dual GIP / GLP-1 agonist with mature clinical data. Retatrutide is a triple agonist adding glucagon receptor activation, producing larger weight-loss signals in Phase 2 research but with less long-term safety data and a steeper side-effect curve.
Tirzepatide is the tested, durable tool with the broadest safety-data footprint. Retatrutide enters the research conversation when the protocol specifically targets glucagon-pathway lipolysis and the research subject tolerates the steeper side-effect ceiling. For most protocols, Tirzepatide is still the default.
Contender A
Tirzepatide
Also: Tirz
Dual GIP / GLP-1 co-agonist driving satiety, glycemic control, and modest lipolysis via GIP arm.
- Half-life
- ~5 days
- Primary use
- Weight loss + metabolic research
- Dose range
- 2.5 mg -> 15 mg weekly
- Cost tier
- $$$ · High sourcing cost
Contender B
Retatrutide
Also: Reta
Triple GIP / GLP-1 / glucagon agonist — glucagon arm drives hepatic lipid mobilization and thermogenic output on top of satiety effects.
- Half-life
- ~6 days
- Primary use
- Aggressive fat loss + hepatic lipid research
- Dose range
- 0.5 mg -> 12 mg weekly
- Cost tier
- $$$ · High sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | Tirz | Reta | Edge |
|---|---|---|---|
Receptor target | GIP + GLP-1 | GIP + GLP-1 + glucagon | Reta |
Evidence maturity | Phase 3 complete + post-market | Phase 2 complete, Phase 3 running | Tirz |
Magnitude of weight change | ~21% in 72 weeks | ~24% in 48 weeks | Reta |
Half-life | ~5 days | ~6 days | Reta |
GI tolerability | Moderate ramp | Steeper ramp, more nausea | Tirz |
Hepatic lipid impact | Neutral-to-mild reduction | Strong steatosis-reduction signal | Reta |
Cardiovascular signal | Well-characterized | Transient HR increase in early data | Tirz |
Research-sourcing cost | Established | Higher, less supply stability | Tirz |
Titration steps | 5 steps over 20 weeks | 5 steps over 20 weeks | Tie |
Regulatory status | FDA-approved for diabetes and obesity | Investigational | Tirz |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
Across protocols we've audited, researchers choose Retatrutide only when the scientific question specifically needs the glucagon arm — hepatic steatosis models, high-BMI research subjects whose metabolic set-point did not move enough on Tirz, or protocols explicitly interested in the thermogenic contribution of glucagon receptor activity. For every other research question, Tirzepatide is still the better tool because the safety envelope is much better mapped.
The transient heart-rate elevation seen in early Retatrutide data is small in magnitude but consistent across trials. Practitioners handling research subjects with any baseline cardiovascular concern skip Reta entirely. The glucagon arm also makes interaction research with any catecholaminergic compound (growth-axis stimulants, metabolic uncouplers) meaningfully more complex — the 20x20 interaction matrix we maintain flags these overlaps.
One consistent mistake in practitioner notes: treating Retatrutide as a straight upgrade from Tirz. It isn't — it's a different tool with a different question. If Tirz is plateauing in a research protocol, the first move is usually a dose-review and diet-composition audit, not a jump to Reta.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Is Retatrutide stronger than Tirzepatide?
+
On weight-loss magnitude in Phase 2 data, yes — ~24% at 48 weeks vs Tirz's ~21% at 72 weeks. But 'stronger' is misleading because Reta's side-effect ceiling arrives sooner and the long-term data isn't there yet.
What does the glucagon arm actually do?
+
Glucagon receptor activation drives hepatic lipid mobilization, increases energy expenditure, and contributes to thermogenesis. In practitioner protocols we've audited, this is most useful in research subjects with documented hepatic steatosis.
Is Retatrutide safe?
+
Phase 2 data looks clean on most endpoints, but Phase 3 is still running. Research subjects with cardiovascular concerns are typically excluded from Reta protocols in our corpus given the transient HR elevation.
Can researchers switch from Tirz to Reta?
+
Yes, but a 1-week washout and a conservative re-titration from 0.5 mg Reta is the pattern we see. Direct dose-equivalency across these molecules isn't established.
What about Semaglutide in this conversation?
+
Semaglutide is the starting tool in most protocols; Tirz is the escalation; Reta is the experimental frontier. See our Semaglutide vs Tirzepatide comparison for the baseline.
Related Comparisons
GLP-1
Semaglutide vs Tirzepatide
Semaglutide is a single-pathway GLP-1 receptor agonist with ~7-day half-life. Tirzepatide is a dual GIP and GLP-1 agonist with ~5-day half-life and meaningfully larger magnitude on both weight and HbA1c endpoints. Both are weekly-administered research peptides; the tradeoff is potency vs tolerability and cost.
ReadGLP-1
Semaglutide vs Liraglutide
Liraglutide is the first-generation GLP-1 receptor agonist — daily injection, ~13-hour half-life. Semaglutide is the second-generation version — weekly injection, ~7-day half-life, stronger magnitude on weight and HbA1c endpoints. The research question is rarely which to pick, it's why someone would still pick Liraglutide.
ReadLongevity
MOTS-c vs SS-31
MOTS-c is a mitochondrial-derived peptide that signals systemically — it activates AMPK, improves insulin sensitivity, and enhances exercise capacity. SS-31 (elamipretide) is a mitochondrial-targeting peptide that binds cardiolipin on the inner mitochondrial membrane, preserving electron-transport-chain function and reducing oxidative damage. Same organelle, completely different mechanism.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.